(Kureczka/Martin Associates) New research suggests the potential utility of BPN14770, a selective PDE4D inhibitor, in the treatment of Fragile X syndrome (FXS) and possibly other autism spectrum disorders. Daily BPN14770 dosing in a mouse Fragile X model showed reduce hyperarousal, improved social interactions and natural behaviors, as well as changes in neuronal dendrite structure. BPM14770 is currently in clinical testing by Tetra Discovery Partners as a prospective treatment for memory and cognitive problems associated with Alzheimer's disease.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2jaeDEp
No comments:
Post a Comment